Personalized pharmacotherapy in diabetes care using clinical pharmacology data of basal insulin analogues.
Advancement in technology led to the development of many insulin analogues in the last three decades. These analogues are characterized by various clinical pharmacology properties that can be utilized in clinical practice to tailor insulin therapy for each patient with diabetes, individually. This paper explores the different aspects of clinical pharmacology data on basal insulin analogues that can influence the choice of basal insulin for a personalized pharmacotherapy.
Division of Endocrinology and Metabolism, Queen's University, Attending Physician, Kingston General Hospital and Hotel Dieu Hospital, 94 Stuart Street, Kingdom, Ontario K7L 3N6, Canada.
Pendar
P
Farahani
D017326:Clinical Trials, Phase III as Topic; D018592:Cross-Over Studies; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D010601:Pharmacology, Clinical / Q000379:methods; D057285:Precision Medicine / Q000379:methods; D016032:Randomized Controlled Trials as Topic
D007004:Hypoglycemic Agents; D007328:Insulin
basal insulin analogues; clinical pharmacology; personalized medicine